Showing results (941-950 of 1,241) with videos related to

Sort By:
Pageof 125
JACC. Heart Failure|October 11, 2020
N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction StudyJustin A Ezekowitz, Christopher M O'Connor, Richard W Troughton, et al.
JACC. Heart Failure|October 10, 2015
Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)Justin L Grodin, Antonio L Perez, Yuping Wu, et al.
Journal of the American College of Cardiology|July 21, 2018
Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF RegistryStephen J Greene, Javed Butler, Nancy M Albert, et al.
American Heart Journal|June 15, 2018
Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failureNancy Luo, Nicholas G Ballew, Emily C O'Brien, et al.
American Heart Journal|September 14, 2025
Developing therapeutics for rare cardiovascular diseasesJoseph B Lerman, Dwight D Koeberl, Shilpi Epstein, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 20, 2026
The Global Parkinson's Disease Genetics (GP2) Genome BrowserZih-Hua Fang, Riley H Grant, Dan Vitale, et al.
JACC. Heart Failure|May 11, 2020
Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF RegistryMuthiah Vaduganathan, Gregg C Fonarow, Stephen J Greene, et al.
JACC. Heart Failure|March 14, 2021
Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart FailureMarat Fudim, Manesh R Patel, Richard Boortz-Marx, et al.
Aging Cell|November 7, 2019
mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative agingCandice E Van Skike, Ai-Ling Lin, Raquel Roberts Burbank, et al.
European Journal of Heart Failure|July 6, 2022
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trialMichele Senni, Wendimagegn G Alemayehu, David Sim, et al.
Pageof 125